110 related articles for article (PubMed ID: 10434233)
1. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems.
Guichard JP; Sauron R; Jones AB
J Clin Pharmacol; 1999 Aug; 39(8):811-6. PubMed ID: 10434233
[TBL] [Abstract][Full Text] [Related]
2. OESCLIM: an advanced delivery system for HRT.
Munoz A
Maturitas; 1999 Nov; 33 Suppl 1():S39-47. PubMed ID: 10661614
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
4. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
5. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jan; 34(1):57-64. PubMed ID: 10687883
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women.
Boyd RA; Zegarac EA; Eldon MA; Sedman AJ; Forgue ST
Biopharm Drug Dispos; 1996 Aug; 17(6):459-70. PubMed ID: 8866037
[TBL] [Abstract][Full Text] [Related]
9. OESCLIM: pre-clinical and clinical profile.
Guy M
Maturitas; 1999 Nov; 33 Suppl 1():S49-55. PubMed ID: 10661615
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a 7-day 17 beta-estradiol transdermal delivery system: effect of application site and repeated applications on serum concentrations of estradiol and estrone.
Boyd RA; Yang BB; Abel RB; Eldon MA; Sedman AJ; Forgue ST
J Clin Pharmacol; 1996 Nov; 36(11):998-1005. PubMed ID: 8973988
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of low-dose transdermal estrogen (Oesclim) in the treatment of menopausal symptoms.
Gadomska H; Barcz E; Cyganek A; Leocmach Y; Chadha-Boreham H; Marianowski L
Curr Med Res Opin; 2002; 18(2):97-102. PubMed ID: 12017217
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
13. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
[TBL] [Abstract][Full Text] [Related]
14. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.
Reginster JY; Albert A; Deroisy R; Colette J; Vrijens B; Blacker C; Brion N; Caulin F; Mayolle C; Regnard A; Scholler R; Franchimont P
Maturitas; 1997 Jun; 27(2):179-86. PubMed ID: 9255753
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of a low-dose of Oesclim (25 mcg daily) in the management of symptomatic menopausal women: a French open-label study.
Elia D; Tamborini A; Leocmach Y; Chadha-Boreham H
Curr Med Res Opin; 2000; 16(2):94-106. PubMed ID: 10893653
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Karara AH; Harrison LI; Melikian AP; Poola N; Morrison D; Bourg D; Bourg L; Zurth C
J Clin Pharmacol; 2014 May; 54(5):520-7. PubMed ID: 24474034
[TBL] [Abstract][Full Text] [Related]
18. OESCLIM: summary of tolerability and safety.
Brackman F
Maturitas; 1999 Nov; 33 Suppl 1():S83-8. PubMed ID: 10661619
[TBL] [Abstract][Full Text] [Related]
19. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara).
Taggart W; Dandekar K; Ellman H; Notelovitz M
Menopause; 2000; 7(5):364-9. PubMed ID: 10993035
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system.
Raynaud JP; Lévrier M; Calaf J; Laur C; Pélissier C
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):309-18. PubMed ID: 15860275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
